ApiFix

Company Overview

Snapshot

Founded in March 2011 by Yizhar Floman and Uri Arnin, ApiFix operated with 11–50 employees. The company raised a total of $8 million across 3 funding rounds from 2 investors before being acquired by Orthopediatrics in April 2020.

Business overview

ApiFix is a Health Tech & Life Sciences company specializing in medical devices for orthopedic treatment. The company develops a minimally invasive scoliosis correction system designed for patients with adolescent idiopathic scoliosis, specifically Lenke type 1 or type 5 with a Cobb angle of 40 to 60 degrees. Unlike traditional aggressive surgical procedures, ApiFix's system involves minimal surgical intervention followed by a multi-month correction process aided by physical therapy. Its core technology, the Internal Brace System, uses an expandable rod with a miniature ratchet mechanism to capture incremental deformity corrections through patient-performed exercises. ApiFix serves the healthcare industry, targeting surgeons, hospitals, and clinics, particularly in pediatrics, across markets like Canada and Europe.

Strategic signal

In April 2020, ApiFix was acquired by Orthopediatrics for at least $67 million, marking a significant exit for the company and validating its minimally invasive scoliosis treatment technology. This acquisition demonstrates the strategic value of innovative medical devices in the pediatric orthopedic market and provides Orthopediatrics with a key product to expand its offerings in spinal deformity correction.

Company Intelligence Q&A

What is ApiFix's primary product?

ApiFix develops a minimally invasive scoliosis correction system, known as the Internal Brace System, for treating adolescent idiopathic scoliosis.

When was ApiFix acquired and by whom?

ApiFix was acquired by Orthopediatrics in April 2020.

What was a key regulatory milestone for ApiFix?

In August 2019, ApiFix received approval from the US Food and Drug Administration (FDA) via a humanitarian device exemption to market its MID-C System for the treatment of progressive adolescent idiopathic scoliosis.

Which investors participated in ApiFix's April 2019 financing round?

In April 2019, ApiFix completed a financing round with participation from The Trendlines Group and B. Braun Melsungen AG.

When did ApiFix reach a significant patient milestone?

In October 2018, ApiFix announced it had surpassed 250 scoliosis patients treated with its system.